 |
Vol.38 No.4 contents | Japanese/English |
- Original Article -
Quality-adjusted Survival Analysis of CIC-therapy (CDDP+IFO+CPT-11+G-CSF) for stage IIIB and IV Non-small Cell Lung Cancer
Akihisa Fujita, Takao Sohda*, Hirotsugu Takabatake, Shigeru Tagaki and Kyuichirou SekineDivision of Respiratory Disease, Hokkaido Keiaikai Minami Ichijo Hospital, *Biometric Analysis Dept., Sionogi & CO., LTD.
A quality-adjusted survival analysis allows one to make treatment comparisons that incorporate differences in QOL associated with various health states. In this analysis, we define as health states the periods of time patients spend: a) in hospital for chemotherapy (toxicity; TOX): b) on an outpatient basis (TWiST: Time without Symptom and Toxicity), and in hospital for conservative therapy (relapse; REL). Utility coefficients to reflect the value of these health states were expressed as ut, uw and ur. If uw were 1 and ut and ur were plotted less than 1, utTOX+uwTWiST+urREL could be a quality-adjusted value relative to TWiST (Q-TWiST). One hundred ninety-six patients with a stage IIIB and IV non-small cell lung cancer were included in 1986-96. One hundred seven patients were given a cisplatin-containing regimen in 1986-93, 38 patients received CIC-regimen (CDDP+IFO+CPT-11+G-CST) in 1994-96 and other 51 patients were treated with supportive care only. In the two years following start to treatment, the prognostic factors for Q-TWiST were investigated employing an automatic interaction detection. Chemotherapy contributed to Q-TWiST with the arbitrary utility coefficient values of ut>ur. CIC-regimen was a significant factor with the arbitrary utility co-efficient values of ut≥0.8 and ur≤0.7. CIC-regimen contributed to QOL marginally.
key words: Non-small cell lung cancer, CPT-11, Quality-adjusted survival analysis
Received: May 11, 1998
Accepted: July 14, 1998
JJLC 38 (4): 323-334, 1998
